{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:15:06Z","timestamp":1788552906129,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jinf.2024.106228","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T08:47:14Z","timestamp":1720601234000},"page":"106228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5329-2751","authenticated-orcid":false,"given":"Matas","family":"Griskaitis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7652-7090","authenticated-orcid":false,"given":"Iris","family":"Thielemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8548-4312","authenticated-orcid":false,"given":"Viktoria","family":"Sch\u00f6nfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7176-0894","authenticated-orcid":false,"given":"Annika","family":"Falman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0798-3057","authenticated-orcid":false,"given":"Ulrich","family":"Reinacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2353-7188","authenticated-orcid":false,"given":"Ole","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Harder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2024.106228_bib1","unstructured":"Robert Koch Institute (RKI). Invasive Meningokokken-Erkrankungen 2012-2015. Epidemiologisches Bulletin; 2016(43):417\u2013485."},{"issue":"8","key":"10.1016\/j.jinf.2024.106228_bib2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1086\/428590","article-title":"Genetic analysis of meningococci carried by children and young adults","volume":"191","author":"Claus","year":"2005","journal-title":"J Infect Dis"},{"issue":"3-4","key":"10.1016\/j.jinf.2024.106228_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijheh.2007.05.006","article-title":"Longitudinal study of meningococcal carrier rates in teenagers","volume":"211","author":"Glitza","year":"2008","journal-title":"Int J Hyg Environ Health"},{"issue":"13","key":"10.1016\/j.jinf.2024.106228_bib4","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.vaccine.2022.02.043","article-title":"Epidemiology and economic burden of meningococcal disease in Germany: a systematic review","volume":"40","author":"Gruhn","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2024.106228_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2019.103571","article-title":"Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis","volume":"134","author":"Purmohamad","year":"2019","journal-title":"Microb Pathog"},{"issue":"4","key":"10.1016\/j.jinf.2024.106228_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","article-title":"The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination","volume":"81","author":"Parikh","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2024.106228_bib7","first-page":"1","article-title":"Epidemiology of invasive meningococcal disease worldwide from 2010\u20132019: a literature review","volume":"151","author":"de Santayana","year":"2023","journal-title":"Epidemiol Infect"},{"issue":"47","key":"10.1016\/j.jinf.2024.106228_bib8","first-page":"521","article-title":"Meningococcal vaccines: WHO position paper, November 2011","volume":"86","author":"World Health Organization (WHO)","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.jinf.2024.106228_bib9","unstructured":"European Centre for Disease Prevention and Control (ECDC). Invasive meningococcal disease ECDC. Annual epidemiological report for 2021. ECDC, Stockholm; 2023."},{"key":"10.1016\/j.jinf.2024.106228_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.1000657","article-title":"Overview of meningococcal epidemiology and national immunization programs in children and adolescents in 8 Western European countries","volume":"10","author":"Pinto Cardoso","year":"2022","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.jinf.2024.106228_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1179\/2047773214Y.0000000126","article-title":"Global practices of meningococcal vaccine use and impact on invasive disease","volume":"108","author":"Ali","year":"2014","journal-title":"Pathog Glob Health"},{"issue":"4","key":"10.1016\/j.jinf.2024.106228_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection","volume":"16","author":"Borrow","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"9320","key":"10.1016\/j.jinf.2024.106228_bib13","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci one year after the introduction of meningococcal C conjugate polysaccharide vaccination","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2024.106228_bib14","unstructured":"European Centre for Disease Prevention and Control (ECDC). Vaccine Scheduler. Meningococcal Disease: Recommended vaccinations 2023. Available from: \u3008https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1\u3009."},{"issue":"17","key":"10.1016\/j.jinf.2024.106228_bib15","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2014serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jinf.2024.106228_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/vaccines9060677","article-title":"Evaluating functional immunity following encapsulated bacterial infection and vaccination","volume":"9","author":"Toh","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.jinf.2024.106228_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vaccine.2011.10.068","article-title":"Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source","volume":"30","author":"Gill","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.jinf.2024.106228_bib18","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jinf.2024.106228_bib19","first-page":"313","article-title":"Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch-Institute - 2019\/2020 [Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut - 2019\/2020]","volume":"34","author":"Standing Committee on Vaccination (STIKO)","year":"2019","journal-title":"Epidemiologisches Bull"},{"key":"10.1016\/j.jinf.2024.106228_bib20","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2024.106228_bib21","unstructured":"ClinicalTrials. U.S. National Institutes of Health; 2022. Available from: \u3008https:\/\/clinicaltrials.gov\/\u3009."},{"key":"10.1016\/j.jinf.2024.106228_bib22","unstructured":"Covidence. Covidence systematic review software Veritas Health Innovation, Melbourne, Australia; 2023. Available from: \u3008www.covidence.org\u3009."},{"key":"10.1016\/j.jinf.2024.106228_bib23","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jinf.2024.106228_bib24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jinf.2024.106228_bib25","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations; 2013. Available from: https\/\/:\u3008www.guidelinedevelopment.org\/handbook\u3009."},{"issue":"5","key":"10.1016\/j.jinf.2024.106228_bib26","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"issue":"7","key":"10.1016\/j.jinf.2024.106228_bib27","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/INF.0b013e31820e8638","article-title":"Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada","volume":"30","author":"De Wals","year":"2011","journal-title":"Pedia Infect Dis J"},{"issue":"27","key":"10.1016\/j.jinf.2024.106228_bib28","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1016\/j.vaccine.2012.04.034","article-title":"Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis","volume":"30","author":"Bettinger","year":"2012","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.jinf.2024.106228_bib29","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/INF.0000000000001278","article-title":"Do dose numbers matter?: evaluation of differing infant and toddler meningococcal c conjugate vaccine programs in Canadian children","volume":"35","author":"Bettinger","year":"2016","journal-title":"Pedia Infect Dis J"},{"issue":"14","key":"10.1016\/j.jinf.2024.106228_bib30","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.vaccine.2018.02.013","article-title":"Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: a phase III, open-label, randomised study","volume":"36","author":"Cutland","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jinf.2024.106228_bib31","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.vaccine.2022.11.048","article-title":"A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children","volume":"41","author":"Cutland","year":"2023","journal-title":"Vaccine"},{"issue":"25","key":"10.1016\/j.jinf.2024.106228_bib32","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","article-title":"An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix\u2122 hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jinf.2024.106228_bib33","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/INF.0b013e31820013d2","article-title":"Immediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age","volume":"30","author":"Booy","year":"2011","journal-title":"Pedia Infect Dis J"},{"issue":"2","key":"10.1016\/j.jinf.2024.106228_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/INF.0b013e3182787bff","article-title":"Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers","volume":"32","author":"Booy","year":"2013","journal-title":"Pedia Infect Dis J"},{"issue":"6","key":"10.1016\/j.jinf.2024.106228_bib35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/INF.0000000000002334","article-title":"Immunogenicity and safety of a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine 6 years after MenC priming as toddlers","volume":"38","author":"Nolan","year":"2019","journal-title":"Pedia Infect Dis J"},{"issue":"1","key":"10.1016\/j.jinf.2024.106228_bib36","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":"Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers","volume":"183","author":"Richmond","year":"2001","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2024.106228_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/INF.0b013e3182784143","volume":"32","author":"Ruiz-Palacios","year":"2013","journal-title":"Pedia Infect Dis J"},{"issue":"6","key":"10.1016\/j.jinf.2024.106228_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100651","article-title":"Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers","volume":"9","author":"Stoof","year":"2014","journal-title":"PLoS One"},{"issue":"50","key":"10.1016\/j.jinf.2024.106228_bib39","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1016\/j.vaccine.2016.10.049","article-title":"Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination","volume":"34","author":"van Ravenhorst","year":"2016","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.jinf.2024.106228_bib40","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1097\/INF.0000000000000897","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.jinf.2024.106228_bib41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.trivac.2014.06.003","volume":"3","author":"Vesikari","year":"2014","journal-title":"Trials Vaccinol"},{"issue":"25","key":"10.1016\/j.jinf.2024.106228_bib42","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2024.106228_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.phrs.2014.10.006","article-title":"Immunogenicity of meningococcal quadrivalent (serogroup A, C, W135 and Y) tetanus toxoid conjugate vaccine: systematic review and meta-analysis","volume":"92","author":"Pellegrino","year":"2015","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.jinf.2024.106228_bib44","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1186\/s12889-020-09946-1","article-title":"Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs","volume":"20","author":"Tin Tin Htar","year":"2020","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.jinf.2024.106228_bib45","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1093\/cid\/ciaa1733","article-title":"Effectiveness of meningococcal vaccines at reducing invasive meningococcal disease and pharyngeal Neisseria meningitidis carriage: a systematic review and meta-analysis","volume":"73","author":"McMillan","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jinf.2024.106228_bib46","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/14760584.2020.1800460","article-title":"Antibody persistence following meningococcal ACWY conjugate vaccine licensed in the European Union by age group and vaccine","volume":"19","author":"Luo","year":"2020","journal-title":"Expert Rev Vaccin"},{"issue":"1","key":"10.1016\/j.jinf.2024.106228_bib47","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/vaccines11010178","article-title":"Efficacy and safety of quadrivalent conjugate meningococcal vaccines: a systematic review and meta-analysis","volume":"11","author":"Conti","year":"2023","journal-title":"Vaccines"},{"issue":"6","key":"10.1016\/j.jinf.2024.106228_bib48","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/10600280211039873","article-title":"MenQuadfi (MenACWY-TT): a new vaccine for meningococcal serogroups ACWY","volume":"56","author":"Huston","year":"2022","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.jinf.2024.106228_bib49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. the Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324001622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324001622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T22:35:01Z","timestamp":1727994901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324001622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0163445324001622"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106228","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106228"}}